Alkermes plc: The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.

Alkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.

Alkermes (ALKS) reported Q2 2026 revenue of $496.01M and net income of $0.50M, with guidance for Q3 2026 revenue of $450M to $470M. The company expects a full-year 2026 GAAP net loss of $95M to $115M. Alkermes paused buybacks after repurchasing 5.32% since 2024 and filed a $311.11M employee share plan shelf.

Simply Wall St reports Alkermes (ALKS) released Q2 2026 results, provided Q3 and full-year guidance implying a GAAP net loss, and filed a new shelf registration. It cites ALKS shares at $49.17, with a consensus price target of $47.69 and a DCF estimate of $95.54, plus analyst targets ranging from $60 to $34.

Alkermes Plc (ALKS) shares rose about 15% after Eli Lilly agreed to buy Centessa for up to $7.8 billion. The deal centers on Centessa’s orexin receptor 2 agonists for sleep disorders, including cleminorexton. RBC reiterated an Outperform rating and $45 target, citing potential value for Alkermes’ orexin program and plans for alixorexton phase 3 in early 2026.

Strategic Evolution and Operational Context Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies.